Summary A phase II trial with mitozolomide was carried out in patients with malignant melanoma, since in preclinical studies this new imidazotetrazine had shown promising effects against human melanoma xenografts. Twenty-one evaluable patients with advanced malignant melanoma were teated with 115mgm-2 of mitozolomide, given orally every 6 weeks. None of the patients had received prior chemotherapy. Two Gibson et al., 1984) that has been found to have a broad spectrum of activity against murine tumours (Hickman et al., 1985) . The effect of mitozolomide on human cancers was examined in preclinical in vitro and in vivo studies, and marked antitumour activity was observed in melanomas, lung carcinomas and in some sarcomas (Fodstad et al., 1985) . Nude mice carrying a xenografted human melanoma were cured of their tumours after treatment with mitozolomide.
Malignant melanoma is a relatively frequent type of cancer which in Norway has shown an increasing incidence during the last decade (Magnus, 1981) . In patients with recurrent disease radiation treatment has limited activity, and the most active chemotherapeutic drugs give response rates of approximately 10-20% only. In our institution DTIC, the most widely used agent, has induced remission in 14% of the more than 100 patients treated. During the last 10-15 years no new compound has proved to be useful in the treatment of malignant melanoma. Encouraging reports of early results with combination chemotherapy regimens are rarely confirmed in sizeable series. In view of these observations it is increasingly recognized that new chemotherapy regimens should be tested as first line treatment in disseminated malignant melanoma.
Mitozolomide (NSC 353451 ) is a new imidazotetrazine (Stevens et al., 1984; Gibson et al., 1984) that has been found to have a broad spectrum of activity against murine tumours (Hickman et al., 1985) . The effect of mitozolomide on human cancers was examined in preclinical in vitro and in vivo studies, and marked antitumour activity was observed in melanomas, lung carcinomas and in some sarcomas (Fodstad et al., 1985) . Nude mice carrying a xenografted human melanoma were cured of their tumours after treatment with mitozolomide.
In phase I trial (Newlands et al., 1985) , the most prominent side effects observed were thrombocytopenia and leucopenia. A Ltd., 1987 Br. J. Cancer (1987 observed already after one course. The criteria for response were: Complete response (CR) is defined as a disappearance of all known disease, determined by two observations not less than 4 weeks apart: partial response (PR) means a decrease by at least 50% in the sum of the products of the largest perpendicular diameters of all measurable lesions, determined by two observations not less than 4 weeks apart; no change is defined as a <50% decrease in total tumour or 25% increase in the size of one or more measurable or evaluable lesions; progressive disease is defined as a >25% increase in the size of at least one indicative lesion or the appearance of a new lesion.
Results
Among 23 eligible patients, there were two early deaths (<6 weeks after first course), unrelated to mitozolomide therapy. One of the other 21 patients received 1 course of treatment, 12 patients received 2 courses, 7 patients received 3 courses and 1 patient received 4 courses of mitozolomide. Twelve patients had dose reductions due to leukopenia or thrombocytopenia grade 3-4. Three dose escalations were undertaken.
Altogether two definite partial responses were seen (>90% tumour volume reduction) (Table II) . In addition one patient had an almost (48%) partial response. All responding patients had lung metastases and one patient had in addition a partial remission of a very large lymph node metastasis in the groin. The duration of the remissions were 10 and 7 + months. Six patients with progression before therapy had stable disease. The remaining 13 patients had progressive disease, and 8 of these had died of their cancer at the time of assessment of the results.
Bone marrow suppression was the main toxic side effect. After the first course of treatment the median WBC and platelet nadirs were 2.4 (1.1-3.6)x 1091-1 and 56 (14-86) x 109 1 -1. For all courses, the nadir values were 2.5 (1.1-3.8)x 1091-I and 59 (14-95)x 1091-1. Haematologic values according to cycle and weeks after treatment are shown in Table III . The number of delayed cycles due to myelosuppression was 17 while 19 courses were reduced in dosage and one escalated.
Five patients had nausea and vomiting of WHO grade 0, eight patients of grade 1, and 8 patients of grade 2. Alopecia was not seen in any of the patients. In general, the subjective side effects of mitozolomide were mild to moderate. During the development and early testing of a series of imidazotetrazines at the University of Aston, Birmingham, one of these, mitozolomide, was found to be very active against murine tumours (Stevens et al., 1984; Hickman et al., 1985) . Subsequent preclinical evaluation of this compound in human tumour models in our institution indicated that mitozolomide might be effective against malignant melanoma (Fodstad et al., 1985) (Fodstad et al., 1985) support this possibility. However, in xenografts of other tumour types, such as lung carcinomas and sarcomas, such cross reactivity has not been observed (Fodstad et any of these drugs, in contrast to the situation with mitozolomide. It may be recommended, therefore, that before a new drug is entered into clinical testing in malignant melanoma, the effect of the compound should be assessed in human tumour models.
